Diamantopoulos E J, Andreadis E A, Tsourous G I, Katsanou P M, Georgiopoulos D X, Nestora K C, Raptis S A
Fourth Department of Internal Medicine, Evangelismos State General Hospital, Athens, Greece.
Int Angiol. 2006 Jun;25(2):179-83.
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, while prediabetes, identified by impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), predicts future development of diabetes mellitus. Although MetS and prediabetes have a strong interrelation, it is unclear whether they denote the same risk for cardiovascular complications. The aim of the study was to compare overweight and obese individuals with MetS and prediabetes in terms of early carotid artery atheromatosis and renal dysfunction.
A total of 524 overweight and obese (body mass index, BMI = or >27 kg/m2) adults, mean age 56.7+/-11.8 years, 264 men and 260 women, were studied. All participants underwent a thorough clinical and laboratory evaluation, including an oral glucose tolerance test. Carotid artery ultrasonography was performed and 24 h urine albumin excretion was measured. NCEP-ATP III and ADA criteria were used for the diagnosis of MetS and prediabetes.
Overall, 129 individuals (24.6%) had MetS without prediabetes and another 59 (11.3%) prediabetes without MetS. Individuals with prediabetes had lower albumin excretion (P=0.033) and more thickened common carotid intima-media in comparison to those with MetS (P=0.032). Furthermore, MetS was associated with higher C-reactive protein levels in comparison to prediabetes (P=0.05).
The MetS seems to have a more pronounced impact on early renal dysfunction than prediabetes, while the latter to early carotid artery structural changes.
代谢综合征（MetS）是一组心血管危险因素，而空腹血糖受损（IFG）和/或糖耐量受损（IGT）所定义的糖尿病前期可预测未来糖尿病的发生。尽管MetS与糖尿病前期密切相关，但尚不清楚它们是否意味着心血管并发症的相同风险。本研究的目的是比较患有MetS和糖尿病前期的超重及肥胖个体在早期颈动脉粥样硬化和肾功能不全方面的情况。
共研究了524名超重及肥胖（体重指数，BMI = 或>27 kg/m²）的成年人，平均年龄56.7±11.8岁，其中男性264名，女性260名。所有参与者均接受了全面的临床和实验室评估，包括口服葡萄糖耐量试验。进行了颈动脉超声检查并测量了24小时尿白蛋白排泄量。采用美国国家胆固醇教育计划成人治疗组第三次报告（NCEP-ATP III）和美国糖尿病协会（ADA）的标准来诊断MetS和糖尿病前期。
总体而言，129名个体（24.6%）患有MetS但无糖尿病前期，另有59名（11.3%）患有糖尿病前期但无MetS。与患有MetS的个体相比，患有糖尿病前期的个体白蛋白排泄量较低（P = 0.033），颈总动脉内膜中层增厚更明显（P = 0.032）。此外，与糖尿病前期相比，MetS与更高的C反应蛋白水平相关（P = 0.05）。
MetS似乎比糖尿病前期对早期肾功能不全的影响更为显著，而糖尿病前期对早期颈动脉结构变化的影响更为明显。
